Consensus Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 17:36:03 13/03/2026 GMT			5-day change	1st Jan Change
96.21 ^USD	+1.20%		-2.05%	+21.00%

03-04	Revolution Medicines Insider Sold Shares Worth $3,644,354, According to a Recent SEC Filing	MT
03-03	Revolution Medicines, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 09:50 AM

Evolution of the Average Target: Revolution Medicines, Inc.

Evolution of the Target Price: Revolution Medicines, Inc.

Changes in Analyst Recommendations: Revolution Medicines, Inc.

1ad595dca88a714f66ff28417c.uQl_0dpoPifDGvPuDP8Q9JfqkiAgWRt-j1EB4t55Pj8.wFFOoapeTBaucqy8NJ59htqv32tBH2w25mFruO81elOMOBjmiDxVfoJwxw~8d919688cefb0a39a11827d963f18bac

Analysts' recommendations: Revolution Medicines, Inc.

08:43am	Analyst recommendations: Adobe, Oracle, Dow, Him & Hers, Whirlpool…
02-27	Revolution's Daraxonrasib has 'Blockbuster' Potential, UBS Says	MT
02-27	UBS Adjusts Revolution Medicines Price Target to $145 From $71, Maintains Buy Rating	MT
02-27	Truist Adjusts Price Target on Revolution Medicines to $116 From $99, Maintains Buy Rating	MT
02-27	Truist Raises Price Target on Revolution Medicines to $116 From $99, Keeps Buy Rating	MT
02-26	Mizuho Trims Price Target on Revolution Medicines to $140 From $143, Keeps Outperform Rating	MT
01-21	RBC Boosts Price Target on Revolution Medicines to $140 From $77, Keeps Outperform, Speculative Risk	MT
01-13	Mizuho Adjusts Price Target on Revolution Medicines to $143 From $90, Maintains Outperform Rating	MT
01-09	Wedbush Raises Price Target on Revolution Medicines to $147 From $80, Keeps Outperform Rating	MT
01-06	Biotech Sector Poised for Growth Driven by Trial Data, Pharma Deals, BofA Says	MT
01-06	BofA Adjusts Price Target on Revolution Medicines to $98 From $82, Maintains Buy Rating	MT
11-06	Wedbush Lifts Price Target on Revolution Medicines to $80 From $77, Keeps Outperform Rating	MT
11-03	Revolution Medicines is Best-Positioned to Execute Targeting RAS-Mutated Cancers, RBC Says	MT
11-03	RBC Initiates Revolution Medicines at Outperform, Speculative Risk With $77 Price Target	MT
21/10/25	Mizuho Initiates Revolution Medicines at Outperform With $90 Price Target	MT
17/10/25	Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment	DJ
11/09/25	Wedbush Raises Price Target on Revolution Medicines to $77 From $73, Keeps Outperform Rating	MT
05/09/25	Truist Initiates Revolution Medicines at Buy With $99 Price Target	MT
18/08/25	LifeSci Capital Initiates Revolution Medicines at Outperform With $80 Price Target	MT
15/08/25	Wells Fargo Initiates Revolution Medicines at Overweight With $67 Price Target	MT
24/06/25	Wedbush Lifts Price Target on Revolution Medicines to $73 From $67, Keeps Outperform Rating	MT
08/01/25	UBS Adjusts Price Target on Revolution Medicines to $71 From $65, Keeps Buy Rating	MT
06/12/24	Wedbush Cuts Price Target on Revolution Medicines to $67 From $70, Keeps Outperform Rating	MT
02/12/24	Stifel Raises Price Target on Revolution Medicines to $80 From $70, Maintains Buy Rating	MT
18/07/24	Barclays Adjusts Price Target on Revolution Medicines to $54 From $52, Maintains Overweight Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	REVOLUTION MEDICINES, INC.					+36.06%
	LONZA GROUP AG					+39.48%
	BEONE MEDICINES AG					+43.6%
	CELLTRION, INC.					+23.28%
	IQVIA HOLDINGS INC.					+44.96%
	ASCENDIS PHARMA A/S					+24.73%
	MEDPACE HOLDINGS, INC.					+10.33%
	EUROFINS SCIENTIFIC SE					+16.29%
	IONIS PHARMACEUTICALS, INC.					+29.8%
	Average					+29.84%
	Weighted average by Cap.					+33.29%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

95.07USD

Average target price

129.35USD

Spread / Average Target

+36.06%

High Price Target

170.00USD

Spread / Highest target

+78.82%

Low Price Target

73.00USD

Spread / Lowest Target

-23.21%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
Truist Securities
Mizuho Securities
RBC Capital Markets
Wedbush
BofA Securities
LifeSci Capital
Wells Fargo Securities
Stifel Nicolaus
Oppenheimer
Needham & Co.
Piper Sandler
HC Wainwright
Raymond James
Goldman Sachs
JPMorgan Chase
SVB Leerink
Guggenheim
J.P. Morgan Chase